The field of ¹⁷⁷Lu radiopharmaceutical therapy is rapidly expanding, which is reflected in the increased use of existing radioligands such as [¹⁷⁷Lu]Lu-DOTATATE or [¹⁷⁷Lu]Lu-PSMA, with new ones such as [¹⁷⁷Lu]Lu-FAPI already in development. Post-therapy quantitative SPECT-CT is important for treatment verification, dosimetry, and trials requiring information on the pharmacokinetics. However, SPECT-CT imaging protocols for ¹⁷⁷Lu are not standardised, which hampers scientific progress in this rapidly developing field. EANM/EARL has therefore formed a task group to define a standardisation and harmonisation programme for quantitative ¹⁷⁷Lu SPECT-CT. The group has proposed a specific protocol, and is in the process of validating it. 

The following file contains the proposed protocol. More details will be shared at the EANM’22 congress. EARL_QSPECT_15Mar22